Commons Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$646K Buy
702
+55
+9% +$55.8K 0.54% 37
2025
Q4
$696K Buy
647
+27
+4% +$25.8K 0.47% 45
2025
Q3
$473K Buy
620
+2
+0.3% +$1.49K 0.31% 60
2025
Q2
$482K Buy
618
+92
+17% +$71.5K 0.37% 54
2025
Q1
$434K Buy
526
+118
+29% +$98.2K 0.4% 52
2024
Q4
$315K Buy
408
+50
+14% +$41.4K 0.29% 66
2024
Q3
$317K Buy
358
+68
+23% +$61.1K 0.35% 43
2024
Q2
$262K Buy
+290
New +$232K 0.32% 42

Other funds holding LLY

Commons Capital's LLY Position: Q1 2026 in Review

Commons Capital increased its Eli Lilly (LLY) stake by 8.5% in Q1 2026, buying an estimated $55.8K and bringing the position to 702 shares worth $646K. The position accounts for 0.54% of the portfolio, ranked #37.

Commons Capital first reported a position in LLY in Q2 2024 and has held it in 8 quarters since. The position peaked at $696K in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Commons Capital held 702 shares of Eli Lilly worth $646K as of Q1 2026.
  • Commons Capital bought 55 Eli Lilly shares in Q1 2026, an estimated $55.8K.
  • Eli Lilly made up 0.54% of Commons Capital's portfolio in Q1 2026, its #37 holding.
  • Commons Capital first reported a position in Eli Lilly in Q2 2024 and has held it in 8 quarters since.
  • Commons Capital's Eli Lilly position peaked at $696K in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Commons Capital's 13F filing for Q1 2026, filed 30 Apr 2026.